EXAI Exscientia
- 4.030
- +0.040+1.00%
- 4.040
- +0.010+0.25%
Exscientia News
Form 144 | Exscientia(EXAI.US) Officer Proposes to Sell 131.4K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 24, $Exscientia(EXAI.US)$ Officer Hallett David intends to sell 30,000 shares of its common stock on Apr 24, with a total market value of approximately $131.4K. Hallett D
Moderna and OpenAI in Pact to Fast-track Drug Development
Exscientia Plc Calls for 2024 Shareholder Votes
Exscientia Is Maintained at Equal-Weight by Morgan Stanley
Exscientia Is Maintained at Equal-Weight by Morgan Stanley
Express News | Morgan Stanley Maintains Equal-Weight on Exscientia, Maintains $7 Price Target
Exscientia Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/22/2024 65.09% Morgan Stanley $7 → $7 Maintains Equal-Weight 01/05/2024 112.26% B of A Securities $11 →
Form 144 | Exscientia(EXAI.US) Officer Proposes to Sell 188.33K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 8, $Exscientia(EXAI.US)$ Officer Krams Michael intends to sell 39,400 shares of its common stock on Apr 8, with a total market value of approximately $188.33K. Source: A
Analysts' Top Healthcare Picks: Healthequity (HQY), Exscientia Plc (EXAI)
Exscientia GAAP EPS of -$0.42 Beats by $0.91, Revenue of $3.1M Misses by $43.5M
Earnings Call Summary | Exscientia(EXAI.US) Q4 2023 Earnings Conference
The following is a summary of the Exscientia Plc (EXAI) Q4 2023 Earnings Call Transcript:Financial Performance:Exscientia concluded the year with a bank balance of $463 million in cash and fixed-term
Exscientia Shares Drop on 4Q Loss, Revenue Miss
By Sabela Ojea Shares of Exscientia on Thursday dropped after the company reported a wider-than-expected loss and a significant drop in revenue for the fourth quarter. At 2:31 p.m. ET, shares were d
Express News | Exscientia Plc Files For Mixed Shelf Of Up To $300M
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersYield10 Bioscience (NASDAQ:YTEN) stock increased by 133.7% to $0.57 during Thursday's pre-market session. The market value of their outstanding shares is at $6.8 million. Immunovant (NASDAQ:IMV
Exscientia Plc Reports Progressive Drug Pipeline
BILI, EXAI and ENVB Among Pre-market Losers
Express News | Exscientia's 2023 Cash, Cash Equivalents And Short Term Bank Deposits As Of December 31, 2023 Were $462.6M Expected To Provide Cash Runway Into 2026
Express News | Exscientia Q4 GAAP EPS $(0.42) Misses $(0.35) Estimate, Sales $3.10M May Not Be Comparable To $17.05M Estimate
Exscientia 4Q Loss/Shr 42c >EXAI
Exscientia 4Q Loss/Shr 42c >EXAI
Press Release: Exscientia Business and Financial Update for the Full Year 2023
Exscientia Business and Financial Update for the Full Year 2023 OXFORD, U.K.--(BUSINESS WIRE)--March 21, 2024-- Exscientia plc (Nasdaq: EXAI) Recent advancements in the Company's pipeline, collabor
Earnings Scheduled For March 21, 2024
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. • InflaRx (NASDAQ:IFRX) is projected to
Analysis
Price Target
No Data
